News

Utrecht, The Netherlands and Zurich, Switzerland, May 16 2011 - Merus BV and ChromaCon AG announced today the award of a EUREKA Eurostars grant with a total budget of €1.8 million to discover and develop bis...

Leiden, The Netherlands, April 26th , 2011 - ISA Pharmaceuticals B.V., a leader in the development of immunotherapeutic products for oncology and infectious diseases, today announced that Mibiton supports IS...

Nijmegen/Utrecht, The Netherlands, April 29th, 2011 - InteRNA Technologies B.V., a biopharmaceutical company developing pathway targeted microRNA (miRNA)-based therapeutics for cancer, is pleased to announce...

ISA Pharmaceuticals B.V., a leader in the development of immunotherapeutic products for oncology and infectious diseases, announced that CTMM, an agency of the Dutch Ministry of Economic Affairs, has awarded...

Utrecht, The Netherlands, January 5th 2010 ‐ Merus announced today that it has received a € 0.75 million grant for the discovery and development of an antibody combination therapy for colon cancer using its...

Date: 16 November, 2010 InteRNA Technologies Awarded EUR 1.3 million Innovation Credit from Dutch Government Utrecht (the Netherlands) - InteRNA Technologies B.V., a biopharmaceutical company developing path...

6 mln euro voor tumorimmunologie en langetermijngevolgen kankerbehandeling 7 december 2010 - Prof.dr.ir. Floor van Leeuwen (NKI-AVL), prof.dr. Kees Melief (LUMC) en prof.dr Carl Figdor (UMC St. Radboud) ont...

Utrecht, the Netherlands (September 20, 2010) - Dutch biopharmaceutical company Merus announced today that Dr. Wolfgang (Wolf) Berthold has joined its Supervisory Board. "We are delighted to appoint Wolf Ber...

Utrecht (the Netherlands) - InteRNA Technologies B.V., a biopharmaceutical company focusing on the development of intelligent microRNA (miRNA)-based therapeutics for cancer, announces the establishment of it...

Bubendorf, Switzerland and Leiden, Netherlands, Bachem (SIX: BANB) and ISA Pharmaceuticals B.V. today announced the conclusion of an agreement for the manufacture of the active ingredients and the supply of...

Merus BV today announced the April 16, 2010 online publication of data by J. de Kruif et. al., in the 'Early View' section of the journal Biotechnology and Bioengineering that demonstrate for the first time...

Syntarga B.V., the emerging Antibody- Drug Conjugate (ADC) company, announces today that it entered into three additional research collaborations since its March 2010 press release. These latest agreements c...

Syntarga B.V., the emerging Antibody-Drug Conjugate (ADC) company, announces today that it entered into research collaborations with two undisclosed top-15 pharma companies. These latest agreements, adding t...

Merus, a biopharmaceutical company located in Utrecht, The Netherlands, announced today that it has closed a €21.7 million ($30.7 million) Series B financing round led by new investors the Novartis Option Fu...

Merus BV, a biopharmaceutical company focused on the discovery and development of mixtures of human therapeutic antibodies, today announced that it has received a grant worth € 0.67 million for the developme...

New England Journal of Medicine Publishes a highly Successful Clinical Study by Leiden University Medical Center and ISA Pharmaceuticals B.V. with a therapeutic HPV vaccine in patients with premalignant vulv...

ORCA Therapeutics BV a biopharmaceutical company in the field of virotherapy, announces that it has obtained an exclusive license from VCN Biosciences SL of Gelida (Barcelona), Spain, to their T1 oncolytic a...

Syntarga B.V. announces that as of today patents have been granted for its proprietary SpaceLink Technology in Europe (EP 1370298 B1), the United States (US 7,223,837), India, China, New Zealand and Australi...

ISA Pharmaceuticals B.V., the Dutch clinical stage biopharmaceutical company focusing on the development of therapeutic vaccines against cancer, today announced the further strengthening of its management te...

Three new small and medium enterprises (SMEs), Syncom, Synvolux Therapeutics and InteRNA Technologies, have joined the public-private partnership TI Pharma by participating in two new projects. The two proje...